We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NuVasive, Inc. announced preliminary revenue results for first-quarter 2020 on Apr 14. The company is slated to release its full financial results for the period on May 6. However, the preliminary results failed to impress the investors as its shares dipped 6.3% to close at $52.90 yesterday, following the announcement.
For first-quarter 2020, NuVasive expects revenues of $259-$261 million, suggesting a decline of 5-5.7% as compared with $274.8 million reported in the first quarter of 2019. The top line is expected to be primarily dented by the global decline in elective surgical procedures since mid-March due to the coronavirus pandemic and government stay-at-home orders. The Zacks Consensus Estimate for the metric is currently pegged at $280.6 million.
As of Mar 31, 2020, NuVasive estimates to have more than $500 million cash on hand and a revolving credit facility of $550 million, which was undrawn as of Mar 31, 2020. However, the company is not in a position to provide more precise estimates for first-quarter 2020 as it is currently conducting its financial close procedure for the quarter.
NuVasive witnessed a fall in elective procedure volumes in the first quarter, which it expects to continue to significantly impact its performance in second-quarter 2020. As of now, the company expects the spine surgery volumes for the remainder of the year to be limited. It is also unable to predict the time and rate of recovery of the elective surgery volumes. Hence, NuVasive has withdrawn its 2020 guidance, which was initially provided on Feb 20, 2020.
Cost Control Measures
Given the adverse impact of the coronavirus pandemic on the demand for elective surgical procedures, NuVasive is adopting measures to control its expenses and overcome the situation. However, given that technological innovation is the key growth driver, NuVasive intends to maintain its levels of R&D investment. The company, from an operation continuity perspective, is managing its distribution and commercial teams to support surgeon partners at present as well as when surgeries start to be on track globally in the future.
Share Price Movement
NuVasive has underperformed its industry over the past three months. The stock has fallen 32.3% compared with a 13.5% decline of the industry.
Zacks Rank & Key Picks
NuVasive currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , National Vision Holdings, Inc. (EYE - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) .
National Vision’s long-term earnings growth rate is estimated at 10.7%. The company presently has a Zacks Rank #2.
Phibro’s long-term earnings growth rate is estimated at 2.1%. It currently carries a Zacks Rank #2.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View
NuVasive, Inc. announced preliminary revenue results for first-quarter 2020 on Apr 14. The company is slated to release its full financial results for the period on May 6. However, the preliminary results failed to impress the investors as its shares dipped 6.3% to close at $52.90 yesterday, following the announcement.
For first-quarter 2020, NuVasive expects revenues of $259-$261 million, suggesting a decline of 5-5.7% as compared with $274.8 million reported in the first quarter of 2019. The top line is expected to be primarily dented by the global decline in elective surgical procedures since mid-March due to the coronavirus pandemic and government stay-at-home orders. The Zacks Consensus Estimate for the metric is currently pegged at $280.6 million.
As of Mar 31, 2020, NuVasive estimates to have more than $500 million cash on hand and a revolving credit facility of $550 million, which was undrawn as of Mar 31, 2020. However, the company is not in a position to provide more precise estimates for first-quarter 2020 as it is currently conducting its financial close procedure for the quarter.
NuVasive witnessed a fall in elective procedure volumes in the first quarter, which it expects to continue to significantly impact its performance in second-quarter 2020. As of now, the company expects the spine surgery volumes for the remainder of the year to be limited. It is also unable to predict the time and rate of recovery of the elective surgery volumes. Hence, NuVasive has withdrawn its 2020 guidance, which was initially provided on Feb 20, 2020.
Cost Control Measures
Given the adverse impact of the coronavirus pandemic on the demand for elective surgical procedures, NuVasive is adopting measures to control its expenses and overcome the situation. However, given that technological innovation is the key growth driver, NuVasive intends to maintain its levels of R&D investment. The company, from an operation continuity perspective, is managing its distribution and commercial teams to support surgeon partners at present as well as when surgeries start to be on track globally in the future.
Share Price Movement
NuVasive has underperformed its industry over the past three months. The stock has fallen 32.3% compared with a 13.5% decline of the industry.
Zacks Rank & Key Picks
NuVasive currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are ResMed Inc. (RMD - Free Report) , National Vision Holdings, Inc. (EYE - Free Report) and Phibro Animal Health Corporation (PAHC - Free Report) .
ResMed has a projected long-term earnings growth rate of 14.4%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
National Vision’s long-term earnings growth rate is estimated at 10.7%. The company presently has a Zacks Rank #2.
Phibro’s long-term earnings growth rate is estimated at 2.1%. It currently carries a Zacks Rank #2.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>